OnCo
technologiesTechnologyPreclinical

Targeting tumour mechanics and pressure

Stiff, high-pressure tumours squeeze their own blood vessels shut, keeping drugs out. Softening them is a way in.

Desmoplastic tumours such as pancreatic cancer generate solid stress that collapses vessels; agents that reduce matrix stiffness (losartan, hyaluronidase, LOXL2 inhibitors) aim to reopen perfusion. PEGPH20, the furthest-advanced hyaluronidase, failed its phase 3 in pancreatic cancer, and losartan combinations remain investigational. The physics is well characterised; converting it into benefit has so far failed.

Generic schematic · not to scale · placeholder for the targeted therapy front
ATP pocket · Inhibitor blocks phosphotransfer · Kinase domain

How it works

Reducing extracellular matrix content or stiffness lowers solid stress, decompresses vessels, and improves delivery of drugs and immune cells.

Strengths
  • Addresses a delivery barrier shared by the deadliest tumours
  • Cheap existing agents to test
  • Measurable with imaging
Limitations
  • PEGPH20 phase 3 failure
  • Loosening the matrix may aid invasion
  • No demonstrated effect on outcomes

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Targeting tumour mechanics and pressure" OR ABSTRACT:"Targeting tumour mechanics and pressure") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Targeting tumour mechanics and pressure, not a curated reading list.

Connected

11top

Pages like this

not linked directly; found by shared links